Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Introgen reports summary data from clinical studies of p53 tumor suppressor Advexin

Nov. 20, 2007

BioLineRx enters worldwide license agreement with Yissum and Hadasit for BL-4060

Nov. 20, 2007

Merck Serono extends rights to Rigel's R-763/AS-703569 to include Japan

Nov. 20, 2007

A TGF-beta inhibitor protects against radiation-induced lung damage

Nov. 20, 2007

Northwestern University initiates enrollment in phase IIb study of Nexavar

Nov. 19, 2007

AEterna Zentaris completes patient enrollment in phase II trial of perifosine

Nov. 19, 2007

MedImmune and Infinity initiate phase II clinical trial of IPI-504 for prostate cancer

Nov. 19, 2007

Infinity regains worldwide rights for hedgehog pathway inhibitor program

Nov. 16, 2007

Enrollment begins for RH1 study in solid tumors or non-Hodgkin's lymphoma

Nov. 15, 2007

Synta initiates SYMMETRY phase III clinical trial of elesclomol in metastatic melanoma

Nov. 15, 2007

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...